Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1983-12-20
|
| pubmed:abstractText |
Twenty-five adults who harbored malignant gliomas received 72 courses of intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) (100 mg/m2) and 67 courses of systemic vincristine (1.0 mg/m2) and procarbazine (100 mg/m2) as induction therapy (BVP) followed by 106 courses of systemic 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (methyl-CCNU) (130 mg/m2), vincristine, and procarbazine as maintenance therapy (MVP). With a 6-week interval between each treatment, the median and range for the number of courses of BVP were 3 and 1 to 4 and those for MVP were 3 and 0 to 14, respectively. Fifteen patients (60%) responded to both BVP and MVP, and 10 (40%) did not. The overall median survival time was 12.7 months (range, 1.8 to 48.5+ months). Two of 3 patients who had recurrent gliomas responded and survived for 37+ to 45+ months. Seven of 10 who had nonirradiated glioblastomas responded and survived for 9 to 22 months. Four who had nonirradiated anaplastic astrocytomas all responded and survived for 38+ to 48.5+ months. Two who also received radiotherapy (1 glioblastoma and 1 primitive neuroectodermal tumor) benefited and survived for 16.9 and 28.5+ months. All who did not respond favorably died within 8 months. During the infusion of BCNU, complications included transient orbital and head pain, periorbital and scleral erythema in all patients, and a focal seizure in 1 (4%). During the 6-month induction periods, leukopenia and thrombocytopenia occurred in 1 (4%), deep vein thrombosis occurred in 9 (36%), pulmonary emboli occurred in 8 (32%), upper respiratory infections occurred in 6 (24%), pneumonia occurred in 9 (36%), and herpes zoster occurred in 1 (4%).(ABSTRACT TRUNCATED AT 250 WORDS)
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0148-396X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
13
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
420-6
|
| pubmed:dateRevised |
2006-4-24
|
| pubmed:meshHeading |
pubmed-meshheading:6314173-Adult,
pubmed-meshheading:6314173-Aged,
pubmed-meshheading:6314173-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:6314173-Astrocytoma,
pubmed-meshheading:6314173-Brain Neoplasms,
pubmed-meshheading:6314173-Carmustine,
pubmed-meshheading:6314173-Carotid Artery, Internal,
pubmed-meshheading:6314173-Combined Modality Therapy,
pubmed-meshheading:6314173-Female,
pubmed-meshheading:6314173-Glioblastoma,
pubmed-meshheading:6314173-Glioma,
pubmed-meshheading:6314173-Humans,
pubmed-meshheading:6314173-Infusions, Intra-Arterial,
pubmed-meshheading:6314173-Male,
pubmed-meshheading:6314173-Middle Aged,
pubmed-meshheading:6314173-Procarbazine,
pubmed-meshheading:6314173-Prognosis,
pubmed-meshheading:6314173-Semustine,
pubmed-meshheading:6314173-Vincristine
|
| pubmed:year |
1983
|
| pubmed:articleTitle |
Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and systemic chemotherapy for malignant gliomas: a follow-up study.
|
| pubmed:publicationType |
Journal Article
|